What happened with RGNX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
REGENXBIO supplies pharmaceutical companies with rights to its NAV technology, which uses adeno-associated virus (AAV) vectors to deliver genes into target tissues. Partners pay for those rights, for development and manufacturing work, and when agreed milestones are reached; sales of licensed treatments also generate royalties. Almost all revenue comes from Novartis Gene Therapies and Nippon Shinyaku. Novartis sells the spinal muscular atrophy treatments Zolgensma and Itvisma, which supply most of REGENXBIO’s royalty revenue.
REGENXBIO also develops its own candidates but has not earned revenue from selling its own products. It works with AbbVie on sura-vec for retinal diseases, with potential milestone payments, shared U.S. profits and royalties outside the United States. Nippon Shinyaku partners on RGX-121 and RGX-111 for rare genetic diseases, while REGENXBIO leads U.S. development and manufacturing. That agreement brings licensing and service revenue, with further payments tied to development progress and eventual sales. Some partner receipts must go to HCR under royalty-sale and financing agreements rather than remain available to fund operations.
The business depends on partner sales and successful development and approval of new therapies. FDA partial clinical holds currently bar new patient recruitment and dosing for RGX-121 and RGX-111 pending additional safety information. The FDA also declined to approve RGX-121’s application, leaving its commercialization dependent on resolving the agency’s concerns.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
REGENXBIO also depends heavily on Nippon Shinyaku, its RGX-121 and RGX-111 development and commercialization partner, which supplied roughly half of its 2025 revenue.
Novartis pays REGENXBIO a share of Zolgensma and Itvisma sales for spinal muscular atrophy as royalties, but its Beovu also competes with REGENXBIO’s wet-AMD pipeline. Watch those two SMA medicines’ sales: they generated $83.2 million in REGENXBIO royalties in 2025.
AbbVie licenses and jointly develops REGENXBIO’s sura-vec for wet AMD and diabetic retinopathy, paying most shared development costs in return for rights tied to future medicine sales; REGENXBIO can receive milestones, half of U.S. net profits or losses, and royalties outside the U.S. First-patient dosing in NAAVIGATE and the subsequent standalone Phase III trial each triggers a $100 million payment from AbbVie.
4D Molecular Therapeutics’ Phase III gene therapy 4D-150 directly challenges REGENXBIO’s sura-vec for longer-lasting wet-AMD treatment. Its two wet-AMD Phase III trials, initiated in 2025, are the competing program to watch; 4D leads global trials and licenses Asia-Pacific commercial rights to Otsuka.
Sarepta Therapeutics sells ELEVIDYS for Duchenne muscular dystrophy, competing with REGENXBIO’s investigational RGX-202, and the companies also dispute patents covering technology used to manufacture AAV gene therapies. Watch ELEVIDYS safety and eligibility news: its U.S. label added a boxed liver-injury warning and removed non-ambulatory patients in November 2025.
Solid Biosciences’ SGT-003 competes with REGENXBIO’s RGX-202 as a gene therapy in development for Duchenne muscular dystrophy. SGT-003’s clinical progress, rather than product sales, is the relevant comparison: Solid’s disclosed programs remain investigational or preclinical.
Denali Therapeutics’ MPS II treatment program competes with REGENXBIO’s RGX-121 for patients with Hunter syndrome. Its treatment’s efficacy, safety and method of administration are the concrete points to compare with RGX-121 as the programs develop.
Ocular Therapeutix’s sustained-release AXPAXLI competes with REGENXBIO’s sura-vec to provide longer-lasting treatment for wet AMD and diabetic retinal disease. AXPAXLI releases medicine locally in the eye through a dissolving hydrogel, offering a different approach from sura-vec’s gene therapy.
EyePoint’s sustained-release DURAVYU competes with REGENXBIO’s sura-vec to reduce treatment burden for retinal vascular disease patients. DURAVYU uses an insert that releases vorolanib as its matrix dissolves, so its sustained-release performance is the comparison to watch against gene therapy.
Kodiak Sciences’ late-stage retinal treatments compete with REGENXBIO’s sura-vec in wet AMD and diabetic retinopathy. Watch its clinical programs rather than sales: Kodiak has no approved products and has generated no product revenue.
Regeneron sells EYLEA and EYLEA HD, established medicines that block VEGF and that REGENXBIO’s sura-vec aims to challenge in wet AMD and diabetic retinopathy. Watch sales of both products together: in 2025, U.S. EYLEA HD sales rose while EYLEA sales fell.
Eli Lilly’s Ixo-vec, acquired with Adverum, competes with REGENXBIO’s sura-vec as a late-stage gene therapy that inhibits VEGF for wet AMD. Watch Ixo-vec’s Phase III ARTEMIS trial, the concrete rival program within Lilly’s broader medicine business.
Ultragenyx pays REGENXBIO for rights to make and commercialize OTC-deficiency and GSDIa treatments through maintenance fees, milestones and sales royalties. Watch which licensed programs continue: parts of the agreement were terminated for certain indications in November 2025.
uniQure licenses REGENXBIO’s AAV9 technology to deliver gene sequences for AMT-260, giving REGENXBIO potential clinical and commercial milestone payments, sales royalties and a share of sublicense fees. AMT-260’s development and any further licensing are the relevant news to watch for this income stream.
Dyne Therapeutics’ Duchenne program competes with REGENXBIO’s RGX-202 to restore dystrophin function in overlapping patient groups, using exon skipping rather than gene therapy. Watch z-rostudirsen’s development, not product sales: Dyne had commercialized no candidates as of December 31, 2025.
BioMarin sells ALDURAZYME for MPS I, which REGENXBIO’s gene therapy RGX-111 could challenge, and their Duchenne development programs also overlap. ALDURAZYME’s $208.5 million in 2025 net product revenue is the specific existing revenue line to watch, rather than BioMarin’s total sales.
Biogen’s SPINRAZA competes for spinal muscular atrophy treatment with Novartis’ Zolgensma and Itvisma, whose sales pay royalties to REGENXBIO. That makes SPINRAZA a rival to REGENXBIO’s licensed-product income rather than to one of its own medicines.
BioMarin Pharmaceuticals Inc earningsBMRN
BioMarin’s report will show how ALDURAZYME sales are holding up in MPS I, giving REGENXBIO’s RGX-111 a market reference in the same disease.
Focus on ALDURAZYME product sales, not BioMarin’s total revenue. Steady or rising sales would show continued demand for an existing MPS I treatment, setting a bar RGX-111 would need to meet; falling sales would point to weaker demand for that treatment, but would not establish that patients will switch to gene therapy.
Novartis AG earningsNVS
Novartis’s report will show how sales of Zolgensma and Itvisma shape the royalties REGENXBIO earns from the two spinal muscular atrophy treatments.
Focus on sales of Zolgensma and Itvisma, not Novartis’s total results. Growing sales would support REGENXBIO’s royalties; weakening sales would put that income stream under pressure, even if Novartis’s other businesses are strong.
ABBVIE INC. earningsABBV
AbbVie’s report offers a read on its sura-vec program with REGENXBIO, including trial milestones tied to payments and the partners’ development spending.
Watch whether NAAVIGATE and the subsequent standalone Phase III trial reach the agreed dosing milestones; each triggers a $100 million payment. Reaching them would bring potential milestone income and show the collaboration advancing; delays could defer payment while REGENXBIO remains responsible for its share of development costs.
Ultragenyx Pharmaceutical Inc. earningsRARE
Ultragenyx’s report can show whether its licensed programs continue, which affects REGENXBIO’s prospects for fees, milestone payments, and sales royalties.
Watch whether Ultragenyx retains and advances the licensed OTC-deficiency and GSDIa programs. Continued programs preserve the possibility of maintenance fees, milestones, and future royalties; termination or retrenchment would reduce REGENXBIO’s opportunities to receive those payments.
Sarepta Therapeutics,, Inc. earningsSRPT
Sarepta Therapeutics’s report will show how ELEVIDYS safety and patient eligibility shape the market for Duchenne gene therapy that includes REGENXBIO’s investigational RGX-202.
Watch ELEVIDYS’s liver safety and patient eligibility. Worsening safety concerns or narrower eligibility would show barriers to reaching people with Duchenne; stable safety and access would show an established treatment continuing to serve this market, where RGX-202 would have to compete if it advances.
REGENXBIO Inc. earningsThis company
REGENXBIO’s report will show how royalties from Novartis products and income from partner development work each support its research spending.
Read royalties alongside license and service revenue, then compare both with operating expenses and cash used in operations. Higher royalties from Zolgensma and Itvisma would show that marketed products are contributing more; if license or development-service income dominates while cash use remains substantial, REGENXBIO still depends more on partner payments, whose timing can hinge on milestones and program progress.
4D Molecular Therapeutics, Inc. earningsFDMT
4D Molecular Therapeutics’s report will show how its Phase III 4D-150 wet-AMD trials are progressing, providing a direct development comparison for REGENXBIO’s sura-vec.
Watch whether 4D-150’s two Phase III wet-AMD trials keep advancing. Continued progress would show another gene therapy moving toward a key test and the competitive challenge to sura-vec developing; delays or setbacks would ease near-term competitive pressure, but would not prove sura-vec works.
